Journal of Clinical Endocrinology & Metabolism, Vol 74, 345-350, Copyright © 1992 by Endocrine Society

ARTICLES

Hair growth effects of oral administration of finasteride, a steroid 5 alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque

AR Diani, MJ Mulholland, KL Shull, MF Kubicek, GA Johnson, HJ Schostarez, MN Brunden and AE Buhl
Upjohn Laboratories, Kalamazoo, Michigan 49001.

A 5 alpha-reductase inhibitor, finasteride, was administered orally at 0.5 mg/day, alone or in combination with topical 2% minoxidil, for 20 weeks to determine the effects on scalp hair growth in balding adult male stumptail macaque monkeys. A 7-day dose-finding study showed that both 0.5- and 2.0-mg doses of the drug produced a similar diminution in serum dihydrotestosterone (DHT) in male stumptails. Hair growth was evaluated by shaving and weighing scalp hair at baseline and at 4-week intervals during treatment to obtain cumulative delta hair weight (sum of the 4-week changes in hair weight from baseline) for the 20-week study. The activity of the 5 alpha-reductase enzyme was assessed by RIA of serum testosterone (T) and DHT at 4-week intervals. The combination of finasteride and minoxidil generated significant augmentation of hair weight (additive effect) compared to either drug alone. Finasteride increased hair weight in four of five monkeys. When the data of the one nonresponsive monkey were excluded, finasteride elicited a significant elevation in hair weight compared to topical vehicle alone. Minoxidil also evoked a significant increase in hair weight compared to vehicle alone. Serum T was unchanged, whereas serum DHT was significantly depressed in monkeys that received either finasteride or the combination of finasteride and minoxidil. These data suggest that inhibition of the conversion of T to DHT by this 5 alpha-reductase inhibitor reverses the balding process and enhances hair regrowth by topical minoxidil in the male balding stumptail macaque.

This article has been cited by other articles:

				A. Tosti, M. Iorizzo, and C. Vincenzi Finasteride Treatment May Not Prevent Telogen Effluvium After Minoxidil Withdrawal Arch Dermatol, September 1, 2003; 139(9): 1221 - 1222. [Full Text] [PDF]

				S. Chanda, C. L. Robinette, J. F. Couse, and R. C. Smart 17beta -Estradiol and ICI-182780 regulate the hair follicle cycle in mice through an estrogen receptor-alpha pathway Am J Physiol Endocrinol Metab, February 1, 2000; 278(2): E202 - E210. [Abstract] [Full Text] [PDF]

				V. H. Price Treatment of Hair Loss N. Engl. J. Med., September 23, 1999; 341(13): 964 - 973. [Full Text] [PDF]

				D. S. Walsh, C. L. Dunn, and W. D. James Improvement in Androgenetic Alopecia (Stage V) Using Topical Minoxidil in a Retinoid Vehicle and Oral Finasteride Arch Dermatol, December 1, 1995; 131(12): 1373 - 1375. [Abstract] [PDF]

				R. S. Rittmaster Finasteride N. Engl. J. Med., January 13, 1994; 330(2): 120 - 125. [Full Text]